Takeda and Denali pen neurodegenerative disease alliance
Newly public biotech Denali Therapeutics Inc. granted Takeda Pharmaceutical Co. Ltd. options to license exclusive global rights to three of its early-stage programs in the neurodegenerative disease space.
- Large Molecule
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com